Royalty Pharma plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RPRX | ROIV | REGN | LGND | JAZZ | ABCL | |
|---|---|---|---|---|---|---|
| Market cap | 33.39B | 24.99B | 78.54B | 6.20B | 14.07B | 4.09B |
| P/E (TTM) | 30.7 | — | 18.9 | 32.8 | 14.9 | — |
| Forward P/E | 10.0 | -20.1 | 12.4 | 26.0 | 8.4 | -16.6 |
| Price/book | 3.8 | 5.9 | 2.4 | 6.4 | 2.9 | 4.3 |
| Dividend yield | 1.65% | — | 0.50% | — | — | — |
| 1-year change | +60.64% | +118.63% | +33.85% | +67.77% | +61.62% | +122.84% |
| Today | +1.49% | −2.40% | +2.18% | +3.09% | −0.76% | +0.72% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RPRX news ›Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Price Today
RPRX Stock Fundamentals & Key Ratios Pluang See today’s Royalty Pharma plc Class A Ordinary Shares (RPRX) stock price, including harga saham Royalty Pharma plc Class A Ordinary Shares, RPRX share value, RPRX stock updates, and latest RPRX…
MIT-Royalty Pharma Faculty Founder Initiative supports biotech innovators
The MIT–Royalty Pharma Faculty Founder Initiative helps translate early-stage biotech research into venture-ready innovation, offering substantial prize funding alongside workshops, classes, and mentorship. The MIT-Royalty Pharma Faculty…
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings - Binding, interest-bearing payment plan converts PMGC’s 5% net sales royalty into…
PMGC secures 5-year royalty stream from Elevai Skincare sale
PMGC (ELAB) announced that the Company and its wholly owned subsidiary, NorthStrive Biosciences, have entered into a fully executed, interest-be... PMGC secures 5-year royalty stream from Elevai Skincare sale PMGC (ELAB) announced that the…
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $235,594.60 in Stock
Marshall Urist also recently made the following trade(s): The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were paid a dividend of $0.2350…
Royalty Pharma officer proposes $236K share sale
Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. Stock Titan Royalty Pharma officer proposes $236K share sale The shares are identified as coming from an equity performance award granted August 7, 2026, and…
Kimbell Royalty Partners upgraded to Strong Buy after record quarter and growth-driving acquisitions.
Kimbell Royalty Partners (KRP) was upgraded to Strong Buy following a record quarter, increased distributions, and two strategic acquisitions that are driving double-digit production growth despite minor dilution. The company offers a…
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Whether it's biotech stocks or regular pharmaceutical stocks, when investors buy a particular name in healthcare, they are making a wager on a single company's pipeline. However, there is one unique name within this space that enables…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
theglobeandmail.com4
-
markets.businessinsider.com2
-
pluang.com2
-
fool.com1
-
marketbeat.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.